Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2018
Price : $35 *
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms CabaGast
- 17 Apr 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2018 Results published in the Journal of Cancer Research and Clinical Oncology.
- 08 Jan 2018 Planned End Date changed from 1 Jun 2017 to 1 Apr 2018.